[Antithrombotic properties of the active metabolite of molsidomine, SIN-1].

Molsidomine and its active metabolite SIN-1 were examined in humans and animals for their fibrinolytic and antithrombotic activity. In humans six and eight hours after ingestion of molsidomine retard (8 mg) a marked shortening of euglobulin clot lysis time was observed. Neither molsidomine nor SIN-1 activated fibrinolysis in vitro. In rabbits SIN-1 decreased the size of arterial and venous thrombus. Similar results were obtained with urokinase.